Method and composition for targeted delivery of therapeutic agents
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMichael R. MCDEVITT, Simone ALIDORI, Nima AKHAVEIN, David A. SCHEINBERG
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions for preventing or reducing kidney injury are disclosed, where the pharmaceutical compositions include (1) siRNAs non-covalently conjugated to functionalized single walled carbon nanotubes (f-SWCNTs) and (2) a pharmaceutically acceptable carrier, where the siRNAs inhibit expression of one or more genes selected from the group consisting of MEP1B and p53 genes.
Claims16
A pharmaceutical composition for preventing or reducing kidney injury, the pharmaceutical composition comprising (1) siRNAs non-covalently conjugated to functionalized single walled carbon nanotubes (f-SWCNTs) and (2) a pharmaceutically acceptable carrier, wherein the siRNAs inhibit expression of MEP1B and p53 genes.
A pharmaceutical composition for reducing acute kidney injury, the pharmaceutical composition comprising (1) siRNAs non-covalently conjugated to functionalized single walled carbon nanotubes (f-SWCNTs) and (2) a pharmaceutically acceptable carrier, wherein the siRNAs inhibit expression of one or more genes selected from the group consisting of MEP1B and p53 genes.
Dependencies are inferred from the claim text.